文献速递特殊人群用药药物不良反应与药物警戒

妊娠期胸腔肿瘤小分子靶向治疗的安全性的VigiBase与系统综述联合分析

Small Molecules Prescribed On- and Off-Label for Thoracic Cancers During Pregnancy: A Combined VigiBase and Systematic Review Analysis.
PubMed 文献 · Drugs · 2026-10-22

该研究结合VigiBase药物警戒不比例分析和系统综述,评估妊娠期用于胸腔肿瘤的已批及超说明书小分子靶向药物的安全性。VigiBase分析显示这些药物与早产、胎儿生长受限、新生儿呼吸窘迫综合征和低出生体重的不比例报告信号相关;系统综述纳入26例妊娠,活产率96.3%,早产率53.8%。阿来替尼单药暴露的10例中未报告临床显著的妊娠并发症,但证据不足以确立其安全性。

要点

  • 妊娠期胸腔肿瘤小分子靶向药与早产、胎儿生长受限、新生儿呼吸窘迫和低出生体重报告信号相关。
  • 系统综述中活产率96.3%,早产率53.8%,妊娠并发症33.3%,新生儿并发症19.2%。
  • 阿来替尼单药暴露10例未报告临床显著妊娠并发症,但数据不足以确立安全性。

核心结论

  • 妊娠期暴露于胸腔肿瘤已批及超说明书小分子药物与选定的不良胎儿结局不比例报告信号相关。
  • 现有临床证据有限,阿来替尼暴露虽未报告临床显著妊娠并发症,但数据不足以确立其安全性。
  • 治疗决策应个体化并在多学科专家环境中制定。

研究设计与样本

  • 基于VigiBase(2006年1月1日至2026年2月24日)的个体病例安全性报告进行药物警戒不比例分析,采用报告比值比(ROR)。
  • 系统综述检索PubMed、EMBASE和Scopus至2026年6月25日,纳入病例报告和病例系列。
  • VigiBase分析纳入15,023份妊娠期抗癌暴露报告,其中162份涉及当前用于胸腔肿瘤的已批或超说明书小分子药物,75份为已批准用于非小细胞肺癌(NSCLC)的药物。
  • 系统综述纳入26名女性(27次妊娠)伴致癌基因驱动的转移性NSCLC。

主要发现

  • 与包括细胞毒药物、免疫检查点抑制剂、其他免疫治疗、抗体药物偶联物、其他分子靶向治疗及未特指抗癌药在内的其他抗癌药相比,目标小分子药物与早产(ROR 2.64;95%CI 1.21-5.75)、胎儿生长受限(ROR 2.10;95%CI 1.15-3.84)、新生儿呼吸窘迫综合征(ROR 3.78;95%CI 1.50-9.57)和低出生体重(ROR 2.27;95%CI 1.18-4.37)的不比例报告相关。
  • 已批准用于NSCLC的小分子药物中,观察到早产(ROR 4.17;95%CI 1.65-10.53)、新生儿呼吸并发症(ROR 2.56;95%CI 1.02-6.42)和低出生体重(ROR 3.55;95%CI 1.61-7.83)的信号。
  • 间变性淋巴瘤激酶(ALK)抑制剂个体病例安全性报告较少,18份阿来替尼报告中14份描述妊娠暴露但无相关妊娠不良药物反应,无法进行阿来替尼特异性不比例分析。
  • 系统综述中活产率96.3%,早产率53.8%,妊娠并发症33.3%,新生儿并发症19.2%,母体结局良好(客观缓解率80.8%)。
  • 10例仅阿来替尼暴露的病例中未报告临床显著的妊娠并发症。

临床怎么用

  • 妊娠期使用胸腔肿瘤小分子靶向药物前应充分评估胎儿风险,关注早产、胎儿生长受限、新生儿呼吸窘迫和低出生体重信号。
  • 治疗决策应个体化,并在多学科专家团队中共同制定。
  • 阿来替尼暴露的现有数据有限,不能据此排除风险,需持续监测妊娠结局。

局限性

  • VigiBase分析基于自发报告,存在报告偏倚和不完整性,不能建立因果关系。
  • 系统综述纳入的临床证据有限,仅26名女性(27次妊娠),样本量小。
  • 阿来替尼个体病例安全性报告较少,无法进行阿来替尼特异性不比例分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thoracic cancers during pregnancy are rare but increasingly encountered because of delayed childbearing and the rising incidence of cancer in younger individuals. Despite guideline recommendations, exposure to targeted small-molecule therapies occurs across all trimesters, but safety data remain limited. OBJECTIVE: To investigate the safety of targeted small-molecule therapies for thoracic cancers during pregnancy by combining VigiBase data with a systematic review. PATIENTS AND METHODS: We performed a pharmacovigilance disproportionality analysis based on the reporting odds ratio (ROR) and a systematic review. Individual case safety reports from VigiBase (January 1, 2006-February 24, 2026) were analysed. A systematic review of PubMed, EMBASE, and Scopus through June 25, 2026 included case reports and case series. RESULTS: The VigiBase analysis included 15,023 reports of anticancer exposure during pregnancy, of which 162 involved small molecules currently used on- and off-label for thoracic cancers, including 75 with approved agents for non-small-cell lung cancer (NSCLC). Compared with other anticancer agents, including cytotoxic drugs, immune checkpoint inhibitors, other immunotherapies, antibody-drug conjugates, molecularly targeted therapies (including biologics and small molecules other than those of interest), and anticancer agents not further specified, the small molecules of interest were associated with disproportionate reporting of premature labor (ROR: 2.64; 95% confidence interval [CI]: 1.21-5.75), foetal growth restriction (ROR: 2.10; 95% CI 1.15-3.84), neonatal respiratory distress syndrome (ROR: 3.78; 95% CI 1.50-9.57), and low birth weight (ROR: 2.27; 95% CI 1.18-4.37). Among approved small molecules for NSCLC, signals were observed for premature labor (ROR: 4.17; 95% CI 1.65-10.53), neonatal respiratory complications (ROR: 2.56; 95% CI 1.02-6.42), and low birth weight (ROR: 3.55; 95% CI 1.61-7.83). Of note, anaplastic lymphoma kinase (ALK) inhibitor ICSRs were fewer, and 14/18 alectinib reports described pregnancy exposure without pregnancy-related ADRs of interest, precluding alectinib-specific disproportionality analysis. The systematic review included 26 women (27 pregnancies) with oncogene-driven metastatic NSCLC. Live births occurred in 96.3% of pregnancies, with 53.8% preterm deliveries, 33.3% pregnancy complications, and 19.2% neonatal complications. Maternal outcomes were favourable (objective response rate 80.8%). There were no clinically significant pregnancy complications reported in the 10 cases involving alectinib exposure alone. CONCLUSIONS: Exposure during pregnancy to small molecules currently used on- and off-label for thoracic cancers was associated with disproportionate reporting signals for selected adverse foetal outcomes. The available clinical evidence remains limited, and although no clinically significant pregnancy complications were reported with alectinib exposure, the current data are insufficient to establish its safety. Treatment decisions should therefore be individualised and made within a multidisciplinary expert setting.

来源:Drugs,查看原文。版权归原作者所有。

引用

  1. Noseda R, Salfi G, Bedussi F, et al. Small Molecules Prescribed On- and Off-Label for Thoracic Cancers During Pregnancy: A Combined VigiBase and Systematic Review Analysis. Drugs. 2026. PMID: 42911352. doi:10.1007/s40265-026-02405-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。